A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Inclusion Criteria:

• Diagnosis of RMS

• At least two documented clinical relapses within the last 2 years prior toscreening, or one clinical relapse in the year prior to screening. No relapse 30days prior to screening and at baseline

• Participants must be neurologically stable for at least 30 days prior torandomization and baseline

• EDSS score, at screening and baseline, from 0 to 5.5 inclusive

• Average T25FWT score over two trials at screening and over two trials at baselinerespectively, up to 150 (inclusive) seconds

• Average 9HPT score over four trials at screening and over four trials at baselinerespectively, up to 250 (inclusive) seconds

• Documented magnetic resonance imaging (MRI) of brain with abnormalities consistentwith MS at screening

• Participants requiring symptomatic treatment for MS and/or physiotherapy must betreated at a stable dose. No initiation of symptomatic treatment for MS orphysiotherapy within 4 weeks of randomization

• Females of childbearing potential, agreement to remain abstinent or use adequatecontraceptive methods

• Female participants without reproductive potential may be enrolled e.g. ifpost-menopausal or if surgically sterile

Exclusion Criteria:

• History of primary progressive MS at screening

• Any known or suspected active infection at screening or baseline (except nailbedinfections), or any major episode of infection requiring hospitalization ortreatment with IV antimicrobials within 8 weeks or treatment with oralantimicrobials within 2 weeks, prior to and during screening

• History of confirmed or suspected progressive multifocal leukoencephalopathy

• History of cancer, including hematologic malignancy and solid tumors, within 10years of screening

• Immunocompromised state

• Receipt of a live or live-attenuated vaccine within 6 weeks prior to randomization

• Inability to complete an MRI or contraindication to gadolinium administration

• Contraindications to mandatory pre-medications for infusion-related reaction (IRRs)

• Known presence of other neurologic disorders that could interfere with the diagnosisof MS or assessments of efficacy and/or safety during the study

• Any concomitant disease that may require chronic treatment with systemiccorticosteroids or immunosuppressants during the course of the study

• Significant, uncontrolled disease that may preclude participant from participatingin the study

• History of or currently active primary or secondary, non-drug-related,immunodeficiency

• Pregnant or breastfeeding or intending to become pregnant

• Lack of peripheral venous access

• History of alcohol or other drug abuse within 12 months prior to screening

• Treatment with any investigational agent within 24 weeks prior to screening ortreatment with any experimental procedure for MS

• Previous use of anti- cluster of differentiation 20 (CD20s) (including ocrelizumab),unless the last infusion was more than 2 years before screening, B-cell count isnormal, and the stop of the treatment was not motivated by safety reasons or lack ofefficacy

• Previous treatment with fingolimod, siponimod, or ozanimod within 6 weeks ofbaseline

• Previous treatment with natalizumab within 4.5 months of baseline

• Previous treatment with interferons beta (1a or 1b), or glatiramer acetate within 2weeks of baseline

• Any previous treatment with mitoxantrone, cladribine, atacicept, alemtuzumab, anddaclizumab - Previous treatment with any other immunomodulatory or immunosuppressivemedication not already listed above without appropriate washout as described in theapplicable local label. If the washout requirements are not described in theapplicable local label, then the wash out period must be five times the half-life ofthe medication

• Any previous treatment with bone marrow transplantation and hematopoietic stem celltransplantation

• Any previous history of transplantation or anti-rejection therapy

• Treatment with IV immunoglobulin (Ig) or plasmapheresis within 12 weeks prior torandomization

• Systemic corticosteroid therapy within 4 weeks prior to screening

• Positive screening tests for active, latent, or inadequately treated hepatitis B

• Sensitivity or intolerance to any ingredient (including excipients) of ocrelizumab

• Any additional exclusionary criterion as per ocrelizumab local label, if morestringent than the above